Cancer Conference Update 1 | 2007


	John Mackey, MD Medical Oncologist, Cross Cancer Institute Professor, Medical and Experimental Oncology University of Alberta Chair of Research, Northern Alberta Breast Cancer Program Director, Cancer International Research Group Edmonton, Canada Click here to download the entire interview		MP3

Track 1

Introduction

Track 2

Second interim analysis of the BCIRG 006 adjuvant trastuzumab clinical trial

Track 3

BCIRG 006: Updated safety data

Track 4

Topoisomerase II as a predictor of benefit from anthracyclines

Track 5

Clinical implications of the updated BCIRG 006 data

Track 6

Phase II trial of trastuzumab/bevacizumab as first-line therapy for HER2-amplified breast cancer

Track 7

Proposed NSABP-B-31/BCIRG 006 replacement trial: TCH with or without bevacizumab

Track 8

Ten-year breast cancer-specific survival and relapse-free survival for HER2-positive T1N0 tumors

Track 9

Effect of hormone receptor status on treatment outcomes for patients with small HER2-positive tumors

Track 10

Phase II trial of capecitabine/trastuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer

Track 11

Prolongation of progression-free survival with trastuzumab in hormone-dependent and HER2-positive metastatic breast cancer

Track 12

Sequential versus combination aromatase inhibitor therapy and trastuzumab

Track 13

EFECT: Exemestane versus fulvestrant following prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with advanced breast cancer

Track 14

Use of a loading dose of fulvestrant


	Peter M Ravdin, MD, PhD Clinical Professor of Medicine The University of Texas Health Science Center at San Antonio San Antonio, Texas Click here to download the entire interview		MP3

Track 1

Introduction

Track 2

Sharp decrease in breast cancer incidence in the United States in 2003

Track 3

Potential effect of changes in hormone replacement therapy on breast cancer incidence

Track 4

Potential factors contributing to the decreased incidence of breast cancer

Track 5

NSABP-B-33: Benefit from exemestane as extended adjuvant therapy after five years of tamoxifen

Track 6

Relationship between quantitative ER and PgR and HER2 status and recurrence in the ATAC trial

Track 7

Benefits of letrozole after five years of tamoxifen are independent of age

Track 8

Benefits of anastrozole over tamoxifen for venous thromboembolic events after five years of treatment in the ATAC trial

Track 9

Zoledronic acid for prevention of bone loss associated with aromatase inhibitors

Track 10

IBIS-2: Effect of anastrozole on cholesterol fractions in postmenopausal women at high risk for breast cancer

Track 11

Risk of cardiovascular events with adjuvant aromatase inhibitors

Track 12

LEAP trial: Direct comparison of safety parameters among aromatase inhibitors for healthy postmenopausal women

Track 13

Adherence with adjuvant anastrozole among women with early-stage breast cancer

Track 14

First report of the ATAC trial endometrial subprotocol at six-year follow-up

Track 15

SABRE study: Effects of risedronate on BMD and bone metabolism in postmenopausal women receiving adjuvant anastrozole

Track 16

Quantitative RT-PCR analysis of ER and PR by Oncotype DX™ indicates distinct associations with prognosis and prediction of tamoxifen benefit

Track 17

Subtypes of breast cancer defined by quantitative RT-PCR analysis of 10,618 tumors

Track 18

Relationship between proliferation genes and expression of hormone and growth factor receptors: Quantitative RT-PCR of 10,618 breast tumors


	Clifford Hudis, MD Chief, Breast Cancer Medicine Service Solid Tumor Division Memorial Sloan-Kettering Cancer Center New York, New York Click here to download the entire interview		MP3